# Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit

> **NIH NIH UM1** · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $4,582,651

## Abstract

PROJECT SUMMARY
The Weill Cornell Medicine – Rutgers New Jersey Medical School Clinical Trials Unit (WCM-NJMS CTU) will
conduct National Institute of Allergy and Infectious Diseases (NIAID)-sponsored network studies of HIV
treatment and HIV prevention; enroll participants from the diverse communities of the New York City (NYC)-
Newark metropolitan area, the epicenter of the HIV epidemic in the U.S. -- home to 14% of Americans living
with HIV; and contribute to the networks' scientific agendas. The unit consists of a central core facility and
three clinical research sites (CRS). The WCM-NJMS CTU provides central research support to the three
CRSs, including investigative and laboratory oversight, financial administration, quality assurance, training, and
community engagement. The three CRSs, WCM-Uptown, WCM-Chelsea, and Rutgers NJMS, are located in
different parts of the NYC-Newark metropolitan area and serve distinct, racially and ethnically diverse
populations of people living with or at-risk for HIV. The WCM-Uptown CRS is located close to Harlem, with
some neighborhoods demonstrating HIV seroprevalence rates of over 5%. The WCM-Chelsea CRS is located
in Chelsea, with some neighborhoods demonstrating the highest seroprevalence rate in NYC of over 8%. The
Rutgers NJMS CRS is located in the center of Newark, serving a predominately African American population
with a high proportion of women, with some neighborhoods demonstrating an HIV seroprevalence rate of over
5%. WCM-NJMS CTU investigators are leaders in the field who are shaping the HIV treatment and HIV
prevention research agendas. They are highly experienced with expertise in HIV cure strategies, antiretroviral
drugs and treatment strategies, tuberculosis, and HIV comordibidities, including hepatitis and neurologic
complications as well as HIV prevention strategies, including HIV pre-exposure prophylaxis (PrEP) and
integrated strategies. Community engagement is a key strength of the WCM-NJMS CTU with both site-specific
and joint Community Advisory Boards (CABs) and a strong record of effectively communicating study results
back to the community. The CTU's three CRSs have successfully enrolled over 1000 participants into a wide
variety of HIV treatment and prevention trials during the current grant cycle with outstanding retention and data
quality. Furthermore, CTU investigators have made substantive scientific and leadership contributions to the
networks. In summary, the WCM-NJMS CTU brings together a diverse group of recognized investigator
leaders who will work with an experienced clinical research staff to conduct cutting-edge HIV treatment and
HIV prevention studies in the NYC-Newark metropolitan areas.

## Key facts

- **NIH application ID:** 10057692
- **Project number:** 2UM1AI069419-15
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** ROY M. GULICK
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $4,582,651
- **Award type:** 2
- **Project period:** 2007-01-10 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10057692

## Citation

> US National Institutes of Health, RePORTER application 10057692, Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit (2UM1AI069419-15). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10057692. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*